NCT06738056Completed
Nerivio Long-term Usage in Patients With Migraine
Real-World Evidence (RWE) Data Analysis of 3-year Usage of Nerivio, a Remote Electrical Neurostimulation (REN) Device In Patients With Migraine
Source: ClinicalTrials.gov · Last updated 17 Jul 2025
Brief summary (registry, in English)
This is a post-marketing real-world evidence study investigates long-term treatment with the Remote Electrical Neuromodulation (REN) wearable Nerivio device over 3 consecutive years in patients with migraine.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 244 (actual)
- First submitted
- 12 Dec 2024
- Start date
- 1 Dec 2024
- Primary completion date
- 20 Dec 2024
- Lead sponsor
- Theranica
- Diseases
- Migraine
- NCT number
- NCT06738056
What you commit to
- Study type: Observational
- Participants enrolled: 244
- From 1 Dec 2024 to the primary completion date, 20 Dec 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- None
Who the study is looking for
- \- Users who began treating with the REN wearable device between December 2019 and September 2021.
- \- Users who treated migraine attacks consecutively for 3 years, with at least 9 months per year
- \- Users with at least one treatment recorded in each of the counted months.
Age in the registry: 12 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Theranica Bio-Elewctronics Inc Coordinator of this site? Confirm its status | Bridgewater | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.